secwatch.observer — SEC 8-K summary
======================================

Issuer:     SEELOS THERAPEUTICS, INC. (—)
CIK:        0001017491
Form:       8-K
Filed at:   2023-03-24T23:59:59+00:00
Accession:  0001104659-23-036612
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seelos Therapeutics adopts amended bylaws for universal proxy rules and enhanced disclosure
--------------------------------------------------------------------------------

- Board approved Amended and Restated Bylaws effective March 23, 2023.
- Amendments require compliance with SEC Rule 14a-19 universal proxy rules, including notice and solicitation requirements.
- Enhanced disclosure requirements for director nominations and stockholder proposals; background info on nominating stockholders and nominees required.
- Stockholders cannot nominate more candidates than board seats; Board may require nominee interviews.
- Stockholders soliciting proxies must use non-white proxy card; white reserved for Board. Remote meetings allowed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1017491/000110465923036612/0001104659-23-036612-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1017491/000110465923036612/tm2310391d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-036612

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer